Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: Post-Hoc analysis of 2 open-label studies

Postgraduate Medicine

Volumn 123, Issue 1, 2011, Pages 94-104

  Capo, James P ^a   Lucente, Vincent ^b   Forero Schwanhaeuser, Sergio ^c   He, Weizhong ^d  

^a Internal Medicine Associates of Atlanta   (United States)

^b Institute for Female Pelvic Medicine   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Bladder diary; Elderly; Overactive bladder; Patient reported outcomes; Solifenacin

Indexed keywords

SOLIFENACIN; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE; QUINUCLIDIN 3' YL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLATE MONOSUCCINATE; QUINUCLIDIN-3'-YL-1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE MONOSUCCINATE; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; TOLTERODINE;

AGED; ANTICHOLINERGIC EFFECT; APTYALISM; ARTICLE; BACKACHE; BLURRED VISION; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE DURATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PERIPHERAL EDEMA; POST HOC ANALYSIS; QUALITY OF LIFE; SALIVARY GLAND DISEASE; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINARY URGENCY; VISUAL ANALOG SCALE; XEROSTOMIA; CLINICAL TRIAL (TOPIC); MIDDLE AGED;

AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE;

EID: 79952790076     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.01.2250     Document Type: Article

References (33)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336.
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int. 2001;87(9):760-766.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1314.
4. Ulahannan D, Wagg A. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009;4:191-196.
5. Patel B, Bavendam T, Badlani G. Use of antimuscarinics in the elderly. ScientificWorldJournal. 2009;9:459-465.
6. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6): 1123-1128.
7. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000;48(7):721-725.
8. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 suppl):S574-S579.
9. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002;8(19 suppl):S598-S607.
10. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367-374.
11. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology. 2002;60(5 suppl 1):50-55.
12. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55(5A suppl):33-46.
13. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebocontrolled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862-870.
14. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543-562.
15. Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001;21(5-6):243-248.
16. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565-578.
17. Kay GG, Abou-Donia MB, Messer WS Jr, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195-2201.
18. Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. BMJ. 1997;315(7119):1363-1364.
19. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol. 2003;60(5):771-773.
20. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med. 2003;349(23):2274-2275.
21. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23(10):2347-2358.
22. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001;49(6):700-705.
23. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14-24.
24. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002;50(5):799-807.
25. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28(11):1935-1946.
26. Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008;30(10):1766-1781.
27. European Medicines Agency. ICH topic E 6(R1). Guideline for good clinical practice. Step 5 Note for guidance on good clinical practice CPMP/ICH/135/95. July 2002; http://www.ema.europa.eu/pdfs/human/ ich/013595en.pdf. Accessed January 25, 2010.
28. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. October 22, 2008. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed January 25, 2010.
29. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079-1086.
30. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563-574.
31. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006;68(2 suppl):3-8.
32. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627-632.
33. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615-626.